About
Neutrolis is a clinical-stage biotechnology company developing engineered enzyme therapies that degrade neutrophil extracellular traps (NETs) to treat autoimmune and inflammatory diseases by addressing their underlying causes.
Explore Neutrolis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.